rbaisconsulting.com
Clin Chem Lab Med. 2013 May;51(5):973-9. doi: 10.1515/cclm-2013-0122.
Although manufacturers are compelled by the European IVD Directive, 98/79/EC, to have traceability of the values assigned to their calibrators if suitable higher order reference materials and/or procedures are available, there is still no equivalence of results for many measurands determined in clinical laboratories. The adoption of assays with metrological traceable results will have a significant impact on laboratory medicine in that results will be equivalent across different laboratories and different analytical platforms. The IFCC WG on Allowable Errors for Traceable Results has been formed to define acceptable limits for metrological traceability chains for specific measurands in order to promote the equivalence of patient results. These limits are being developed based on biological variation for the specific measurands. Preliminary investigations have shown that for some measurands, it is possible for manufacturers to assign values to assay calibrators with a measurement uncertainty that allows the laboratory enough combined uncertainty for their routine measurements. However, for other measurands, e.g., plasma sodium, current assays are too imprecise to fulfil limits based on biological variation. Although an alternative approach based on probability theory is being investigated, the most desirable approach would be for industry to improve measurement methods so that they meet clinical requirements.
虽然制造商受到欧洲体外诊断指令(98/79/EC)的约束,必须对其校准品赋值进行可追溯性,如果有合适的更高级别的参考物质和/或程序可用,但在临床实验室中,许多测量指标的结果仍然没有等效性。采用具有可溯源计量结果的检测方法将对实验室医学产生重大影响,因为不同实验室和不同分析平台的结果将具有等效性。国际临床化学联合会(IFCC)可溯源结果允许误差工作组已经成立,目的是为特定测量指标的可溯源计量链定义可接受的限制,以促进患者结果的等效性。这些限制是基于特定测量指标的生物学变异来制定的。初步研究表明,对于某些测量指标,制造商有可能为检测校准品赋值,其测量不确定度使实验室有足够的综合不确定度进行常规测量。然而,对于其他测量指标,例如血浆钠,当前的检测方法不够精确,无法满足基于生物学变异的限制。虽然正在研究基于概率论的替代方法,但最理想的方法是行业改进测量方法,以满足临床需求。